US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Invesco S&P Spin-Off ETF

87.81

+1.301.50%

Post-market: 87.820.0117+0.01%16:04 EDT

Volume:12.44K

Turnover:1.08M

Market Cap:73.76M

PE:121.96

High:87.82

Open:86.80

Low:86.80

Close:86.51

Loading ...

Overview Company News Filings

Press Release: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF

Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F

Keurig Stock Rises 5% YTD: Should Investors Buy Now or Wait?

Center for Social Dynamics, Leader in ABA Services, Taps VR Startup to Scale Delivery of ABA Virtual Services

/C O R R E C T I O N from Source -- i-80 Gold Corp/

Keurig Dr Pepper (KDP): Among Stocks Insiders Spent The Most Money On Recently

i-80 Gold Announces Positive Updated Preliminary Economic Assessment on the Cove Project, Nevada; After-Tax NPV(5%) of $271 Million with an After-Tax IRR of 30% at US$2,175/oz Au

Patient Reported Outcomes for GRAIL's Galleri® Multi-Cancer Early Detection Blood Test Published in Lancet Oncology

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CSD/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSD\",,,,,undefined,":{"symbol":"CSD","market":"US","secType":"STK","nameCN":"Invesco S&P Spin-Off ETF","latestPrice":87.8083,"timestamp":1753473600000,"preClose":86.51,"halted":0,"volume":12437,"hourTrading":{"tag":"盘后","latestPrice":87.82,"preClose":87.8083,"latestTime":"16:04 EDT","volume":4,"amount":351.2332,"timestamp":1753473850356},"delay":0,"floatShares":840000,"shares":840000,"eps":0.72,"marketStatus":"Market Closed","change":1.2983,"latestTime":"07-25 16:00:00 EDT","open":86.804245,"high":87.82,"low":86.804245,"amount":1080718.746825,"amplitude":0.011741,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0.72,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1753689600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":86.51,"sharesOutstanding":840000,"nav":86.46064,"aum":72626937.6,"dividendRate":0.001594,"bidAskSpread":0.002905,"postHourTrading":{"tag":"盘后","latestPrice":87.82,"preClose":87.8083,"latestTime":"16:04 EDT","volume":4,"amount":351.2332,"timestamp":1753473850356},"volumeRatio":1.6016742120113165,"impliedVol":0.0996,"impliedVolPercentile":0.544},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSD\",,,,,undefined,":{"symbol":"CSD","floatShares":840000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.6016742120113165,"shares":840000,"dividePrice":0.14,"high":87.82,"amplitude":0.011741,"preClose":86.51,"low":86.804245,"week52Low":63.06,"pbRate":"--","week52High":93.6,"institutionHeld":0,"latestPrice":87.8083,"eps":0.72,"divideRate":0.001594,"volume":12437,"delay":0,"ttmEps":0.72,"open":86.804245,"prevYearClose":82.16,"prevWeekClose":85.145,"prevMonthClose":83.9,"prevQuarterClose":83.9,"fiveDayClose":85.145,"twentyDayClose":83.7746,"sixtyDayClose":73.2878},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSD\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2535108870","title":"Press Release: Rein Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2535108870","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535108870?lang=en_us&edition=fundamental","pubTime":"2025-05-16 04:09","pubTimestamp":1747339740,"startTime":"0","endTime":"0","summary":"RENEW Phase 2 trial evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis  initiated with topline interim data expected in the first half of 2026. Two abstracts accepted to the American Thoracic Society  2025 International Conference. Cash runway extended following previously announced warrant transactions and private placement. \"Rein has completed a multitude of key accomplishments since the beginning of the year, and we are particularly excited to have initiated the Phase 2 RENEW trial of LTI-03 in patients with IPF,\" said Brian Windsor, Ph.D., President and Chief Executive Officer of Rein Therapeutics. \"We have taken several strategic steps to prepare for this trial. Our LTI-03 program continues to evolve as we entered into a collaboration with Qureight to bring cutting-edge technology to our imaging and data analysis and obtained patents covering our novel formulation and administration methods. We are committed to continuing this momentum of ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","RNTX","ATS","CSD","BK4007","BK4139","LENZ","BK4539"],"gpt_icon":0},{"id":"2532075868","title":"Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF","url":"https://stock-news.laohu8.com/highlight/detail?id=2532075868","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532075868?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:00","pubTimestamp":1746097200,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, May 1, 2025 /PRNewswire/ -- Rein Therapeutics  , a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, and Qureight Ltd, a Core Imaging Laboratory developing deep-learning image analytics, today announced a collaboration for the integration of Qureight's deep-learning platform into Rein's planned Phase 2 trial of its lead asset LTI-03, a novel, multi-pathway, Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis .Dr. Muhunthan Thillai, Chief Executive Officer of Qureight, said, \"We're delighted that our core platform and AI technology will be supporting Rein Therapeutics in advancing its treatment, LTI-03, for patients with IPF. Our AI tools will provide precise, quantitative insights into","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rein-therapeutics-qureight-ltd-announce-110000614.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rein-therapeutics-qureight-ltd-announce-110000614.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RNTX","CSD","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2530472503","title":"Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2530472503","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530472503?lang=en_us&edition=fundamental","pubTime":"2025-04-28 19:00","pubTimestamp":1745838000,"startTime":"0","endTime":"0","summary":"AUSTIN, Texas, April 28, 2025 /PRNewswire/ --Rein Therapeutics  , a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications,today announced that an abstract has been accepted at the American Thoracic Society  2025 International Conference taking place May 18-21, 2025 in San Francisco, CA.Details of the poster presentation are as follows:. Presentation Title: Evaluating Alveolar Regenerative Properties of Caveolin Scaffolding Peptides  in Three Dimensional  Alveolospheres from IPF and Normal Donor Lung Samples Poster #: P1463Session: B75 Targeting Cellular Senescence, Immune Dysregulation, and Metabolism in Lung Injury and FibrosisDate & Time: Monday, May 19, 2025, at 11:30 AM PT/ 2:30 PM ET. Rein Investor Relations & Media Contact:Argot Partnersrein@argotpartners.com 212-600-1902","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rein-therapeutics-announces-abstract-accepted-110000640.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rein-therapeutics-announces-abstract-accepted-110000640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","AFG","LENZ","BK4007","CSD","RNTX","ATS","BK4107","BK4139","BK4117"],"gpt_icon":0},{"id":"2527991034","title":"Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F","url":"https://stock-news.laohu8.com/highlight/detail?id=2527991034","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527991034?lang=en_us&edition=fundamental","pubTime":"2025-04-15 19:00","pubTimestamp":1744714800,"startTime":"0","endTime":"0","summary":"Manuscript highlights the effects of caveolin scaffolding domain peptide LTI-2355 on myeloid cell activity in Idiopathic Pulmonary Fibrosis  and Post-Acute Sequelae of COVID Fibrosis . AUSTIN, Texas, April 15, 2025 /PRNewswire/ --Rein Therapeutics  , a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced a publication highlighting the therapeutic potential of Caveolin-1-related peptide LTI-2355 in Idiopathic Pulmonary Fibrosis  and Post-Acute Sequelae of COVID Fibrosis  in the peer-reviewed journal, Biomedicines.Rein Therapeuticsis a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class therapies to address significant unmet medical needs in orphan pulmonary and fibrosis indica","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/rein-therapeutics-announces-publication-biomedicines-110000178.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/rein-therapeutics-announces-publication-biomedicines-110000178.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RNTX","BK4139","LENZ","BK4007","CSD"],"gpt_icon":0},{"id":"2526846941","title":"Keurig Stock Rises 5% YTD: Should Investors Buy Now or Wait?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526846941","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526846941?lang=en_us&edition=fundamental","pubTime":"2025-04-09 00:16","pubTimestamp":1744128960,"startTime":"0","endTime":"0","summary":"Keurig Dr Pepper Inc. KDP has displayed a robust graph, reflecting the continued rise in its share price in the past few months. The KDP stock’s momentum is attributed to the success of its strong brand strength and increased volumes, contributing positively to its performance. The company is making significant progress in reshaping its portfolio with the acquisition of GHOST Lifestyle, which is slated to strengthen its position in high-growth categories.KDP is gaining from a sturdy Refreshment Beverages unit and solid market share growth. Its consumer-centric innovation model, portfolio expansion into high-growth categories, and solid route-to-market capabilities appear encouraging.In the year-to-date period, the company’s shares have risen 5.2%, surpassing the broader Zacks Consumer Staples sector’s growth of 2.8% and the S&P 500 index’s decline of 14.1%.At the current price of $33.60, shares of this Burlington, MA-based beverage company reflect a 12.2% discount to its recent 52-week","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/keurig-stock-rises-5-ytd-161600754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["FMXUF","BK4158","LU2125910500.SGD","LU0321505439.SGD","LU0985481810.HKD","BK4585","CSD","LU0823046577.USD","BK4177","FMX","LU0306806265.USD","BK4211","ISBC","BK4566","LU0225771236.USD","LU0823046494.USD","LU1989763427.SGD","IE00BJTD4V19.USD","BK4505","LU0788109048.HKD","BK4588","LU0321505868.SGD","LU2045819591.USD","BK4535","IE00BJTD4N35.SGD","LU0572108347.SGD","LU0256859116.SGD","LU0541501648.USD","LU0541502299.USD","LU0306807586.USD","TAP","LU1989763690.USD","KDP","LU0396314238.USD","LU0106259046.USD","IE00B3T34201.USD","LU0225284248.USD","LU0072463663.USD","PRMB"],"gpt_icon":0},{"id":"2524259389","title":"Center for Social Dynamics, Leader in ABA Services, Taps VR Startup to Scale Delivery of ABA Virtual Services","url":"https://stock-news.laohu8.com/highlight/detail?id=2524259389","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524259389?lang=en_us&edition=fundamental","pubTime":"2025-04-03 20:00","pubTimestamp":1743681600,"startTime":"0","endTime":"0","summary":"Center for Social Dynamics has selectedFloreo to expand delivery of immersive, virtual services incorporating VR autism therapy to schools nationwide.WASHINGTON, April 3, 2025 /PRNewswire/ --Center for Social Dynamics , leader in providing and innovating behavioral health services, today announced the expansion of a groundbreaking partnership with Floreo, pioneering developer of virtual reality  lessons that help teach life skills to autistic and neurodiverse children. Leveraging CSD's national delivery platform and immersive programming and Floreo's VR-enabled curriculum, the partnership aims to improve school-based access to specialized care. In 2023, Floreo became the first VR autism technology to receive the Food and Drug Administration's  breakthrough device designation.Center for Social Dynamics, recently acquired byGoldman Sachs Alternatives, delivers over 1 million hours of high-quality, evidence-based care for youth with autism annually across a growing number of states and al","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/center-social-dynamics-leader-aba-120000071.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/center-social-dynamics-leader-aba-120000071.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0742534661.SGD","LU2471134523.USD","LU2471134879.HKD","GS","LU2237443382.USD","LU2237438978.USD","LU2237443465.HKD","LU2750360641.GBP","BK4504","LU2471134952.CNY","LU1791807156.HKD","BK4127","IE00B19Z3581.USD","BK4588","LU1868836914.USD","LU1868836591.USD","CSD","LU2237443895.HKD","LU2237443978.SGD","LU0251131958.USD","IE00BSNM7G36.USD","VR","IE0004086264.USD","IE00B19Z3B42.SGD","LU2237443622.USD","LU1868836757.USD","LU2237443549.SGD","IE00BFXG1179.USD","LU0251142724.SGD","BK4552","BK4533","IE0002270589.USD","LU1668664300.SGD","LU2750360997.AUD","LU0061475181.USD","BK4516","BK4550","BK4585","IE0004091025.USD","LU1868837300.USD","LU0048573561.USD","LU0106831901.USD","LU2471134796.USD","LU0096364046.USD","IE0034235188.USD","LU1868837136.USD"],"gpt_icon":0},{"id":"2513246646","title":"/C O R R E C T I O N from Source -- i-80 Gold Corp/","url":"https://stock-news.laohu8.com/highlight/detail?id=2513246646","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513246646?lang=en_us&edition=fundamental","pubTime":"2025-02-22 07:01","pubTimestamp":1740178860,"startTime":"0","endTime":"0","summary":"In the news release, i-80 Gold Announces Positive Updated Preliminary Economic Assessment on the Cove Project, Nevada; After-Tax NPV(5%) of $271 Million with an After-Tax IRR of 30% at US$2,175/oz Au, issued 12-Feb-2025 by i-80 Gold Corp over PR Newswire, we are advised by the company that they wish to add a correction as to the nature of the release as a sub-headline, with an updated headline. The complete, corrected release follows:. This news release is being republished to confirm that it constitutes a designated news release for the purpose of the Company's prospectus supplement dated August 12, 2024 to its short form base shelf prospectus dated June 21, 2024. The complete, corrected press release follows:. This news release constitutes a \"designated news release\" for the purposes of the Company's prospectus supplement dated August 12, 2024, to its short form base shelf prospectus dated June 21, 2024.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/c-o-r-r-e-230100775.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/c-o-r-r-e-230100775.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4017","IAUX","CSD","EIS"],"gpt_icon":0},{"id":"2512367654","title":"Keurig Dr Pepper (KDP): Among Stocks Insiders Spent The Most Money On Recently","url":"https://stock-news.laohu8.com/highlight/detail?id=2512367654","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512367654?lang=en_us&edition=fundamental","pubTime":"2025-02-20 03:52","pubTimestamp":1739994729,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Stocks Insiders Spent The Most Money On Recently. In this article, we are going to take a look at where Keurig Dr Pepper  stands against other stocks insiders spent the most money on recently.As the broader market continues to rise this year, we thought it would be interesting to highlight some stocks that have seen significant insider buying recently. Insiders—such as executives and directors—often have valuable insights into a company’s strategy, plans, and future initiatives. For instance, when a CEO or CFO invests their own money to purchase company shares, it can be seen as a strong vote of confidence in the company’s prospects. When an insider makes a substantial financial commitment, it often signals an even higher level of confidence in the company’s future performance.What are some of the stocks that have seen the most insider investment recently?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/keurig-dr-pepper-kdp-among-195209368.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSD","KDP","LU1989763427.SGD","BK4566","BK4177","BK4585","IE00BJTD4N35.SGD","BK4505","BK4588","IE00BJTD4V19.USD","LU1989763690.USD","BK4535"],"gpt_icon":0},{"id":"2511536679","title":"i-80 Gold Announces Positive Updated Preliminary Economic Assessment on the Cove Project, Nevada; After-Tax NPV(5%) of $271 Million with an After-Tax IRR of 30% at US$2,175/oz Au","url":"https://stock-news.laohu8.com/highlight/detail?id=2511536679","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511536679?lang=en_us&edition=fundamental","pubTime":"2025-02-13 06:05","pubTimestamp":1739397900,"startTime":"0","endTime":"0","summary":"RENO, Nev., Feb. 12, 2025 /PRNewswire/ - i-80 GOLD CORP.   is pleased to announce the results of an updated preliminary economic assessment  for the Cove Project , an advanced underground exploration project located on the Battle Mountain-Eureka Trend in Northern Nevada, United States. The 2025 PEA confirms that the high-grade Cove Project has the potential to become a key component of the Company's regional \"hub-and-spoke\" mining and processing strategy.The 2025 PEA replaces the previous PEA for the Project completed in 2021 . The Study has been updated to reflect a remodeling of the deposit using a more confined mining geometry, further advancement of the hydrology model, as well as using updated precious metals prices, capital and operating costs. All amounts are in United States dollars, unless otherwise stated.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/80-gold-announces-positive-updated-220500064.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/80-gold-announces-positive-updated-220500064.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NPV","CSD","IRR","BK4017","IAUX","EIS"],"gpt_icon":0},{"id":"2503451563","title":"Patient Reported Outcomes for GRAIL's Galleri® Multi-Cancer Early Detection Blood Test Published in Lancet Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2503451563","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503451563?lang=en_us&edition=fundamental","pubTime":"2025-01-14 07:49","pubTimestamp":1736812140,"startTime":"0","endTime":"0","summary":"Analysis of Patient Reported Outcomes From PATHFINDER Indicate Minimal Patient Distress Associated with Multi-Cancer Early Detection Testing. MENLO PARK, Calif., Jan. 13, 2025 /PRNewswire/ -- GRAIL, Inc.  a healthcare company whose mission is to detect cancer early when it can be cured, today announced that patient-reported outcomes  assessing patient perspectives from the PATHFINDER study were published in Lancet Oncology. The PATHFINDER study included secondary and exploratory outcomes with the objective of assessing PRO and perceptions of multi-cancer early detection  testing.\"As the pioneer in multi-cancer early detection, GRAIL is committed to not only evaluating the performance of the Galleri test but also the impact of MCED screen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/patient-reported-outcomes-grails-galleri-234900247.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/patient-reported-outcomes-grails-galleri-234900247.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4023","GRAL","CLIA","PSA","BK4217","BK4588","BK4084","BK4585","BK4139","CSD","PRO","BK4533"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSD\",params:#limit:5,,,undefined,":[{"date":"2024-12-23","symbol":"CSD","amount":0.13729,"announcedDate":"2024-12-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-23","defaultRemindTime":1734964200000,"name":"Invesco S&P Spin-Off ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-27","payableDate":"2024-12-23","currency":"USD","dateTimestamp":1734930000000,"payDate":"2024-12-27"},{"date":"2023-12-18","symbol":"CSD","amount":0.33167,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"Invesco S&P Spin-Off ETF","recordDate":"2023-12-22","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-22"},{"market":"US","date":"2022-12-19","symbol":"CSD","amount":0.45,"defaultRemindTime":1671460200000,"name":"Invesco S&P Spin-Off ETF","recordDate":"2022-12-23","payableDate":"2022-12-20","currency":"USD","type":"dividend","dateTimestamp":1671426000000},{"market":"US","date":"2021-12-20","symbol":"CSD","amount":0.4547,"defaultRemindTime":1640010600000,"name":"Guggenheim Spin-Off ETF","recordDate":"2021-12-31","payableDate":"2021-12-21","currency":"USD","type":"dividend","dateTimestamp":1639976400000},{"market":"US","date":"2020-12-21","symbol":"CSD","amount":0.54891,"name":"Guggenheim Spin-Off ETF","recordDate":"2020-12-31","payableDate":"2020-12-22","currency":"USD","type":"dividend","dateTimestamp":1608526800000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSD\",market:\"US\",,,undefined,":[{"executeDate":"2015-12-24","recordDate":"2015-12-29","paymentDate":"2015-12-31","value":1.0016,"currency":"USD"},{"executeDate":"2016-12-23","recordDate":"2016-12-28","paymentDate":"2016-12-30","value":0.702,"currency":"USD"},{"executeDate":"2019-12-23","recordDate":"2019-12-24","paymentDate":"2019-12-31","value":0.54659,"currency":"USD"},{"executeDate":"2020-12-21","recordDate":"2020-12-22","paymentDate":"2020-12-31","value":0.54891,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.4547,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CSD\",market:\"US\",delay:false,,,undefined,":{}}}